The Relationships between Toll-like Receptors and RP215-associated Immunoglobulins Expressed by Cancer Cells

Gregory Lee1,2*, Cheng-Yuan Huang1, Hao Zhang1,2 and Yiting Tang1,2

1UBC Center for Reproductive Health, Vancouver, Canada
2Department of Pathology, Shantou University, Shantou, China

Abstract

Relationships between the expressions of immunoglobulins by cancer cells and those of toll-like receptors were investigated through comparative gene regulation studies to understand their roles and mechanisms of action in cancer immunology. RP215 is a monoclonal antibody generated in 1987 and found to recognize the carbohydrate-associated epitope which is detected preferentially in the heavy chains of immunoglobulins expressed by cancer cells, but not in normal immune cells. In this report, RP215 was used to study interactions of cancerous immunoglobulins with toll-like receptors in the innate immunity of cancer cells. From gene regulation studies, with OC-3-VGH ovarian and C-33A cervical cancer cell lines, it was demonstrated that the expressions of cancerous toll-like receptors (TLR-2, -3, -4, -6, -7 and -9) are strongly influenced by the incubation of cancer cells with RP215 or antibodies against human IgG. For example, both RP215 and anti-human IgG were found in high correlation to up-regulate TLR-3 expressions by 2.5 and 3.5 fold, respectively, whereas those of TLR-4 and TLR-9 were down-regulated by 50% to 80% of the untreated. Based on these studies, it is reasonable to postulate that cancerous immunoglobulins are functionally related to toll-like receptors in the innate immunity of cancer cells. With RP215 as unique probe for cancerous immunoglobulins, comparative gene regulation studies were performed to investigate interactions or associations between cancerous immunoglobulins or related genes and TLRs in cancer cells. By using semi-quantitative RT-PCR method, results summarized in this review may shed light to our current understanding of cancer immunology which may operate independently of our normal immune system within our body [15,16].

Gene Regulations and Interactions between Cancer Cell-expressed Toll-like Receptors and Immunoglobulins

Toll-like receptors are best characterized family of pattern recognition receptors (PRRs) which recognize foreign microbes derived from bacteria and/or virus, known in general as pathogens-associated molecular patterns (PAMPS) [17-19]. Activation of TLRs with their ligands may evoke inflammatory response and protect the host from spreading massive pathogens after infection. This is commonly known as innate immune response either in normal or cancer cells. So far, at least nine different TLRs and the corresponding ligands have been identified and expressed among different types of cancer in humans [11,20,21].

Keywords: RP215; CA215; Cancerous immunoglobulins; Toll-like receptors; Innate immunity

Abbreviations: GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase; IgG: Immunoglobulin G; IgSF: Immunoglobulin Superfamily; Proteins: Mab Monoclonal Antibody; NFκB-1: Nuclear Factor kappa-B p105 Subunit 1; PAMP: Pathogens-associated Molecular Patterns; PRRs: Pattern Recognition Receptors; RT-PCR: Reverse Transcription Polymerase Chain Reaction; TLR: Toll-like Receptor

Background Information

Since the initial discovery of cancerous immunoglobulins decades ago, a substantial progress has been made regarding their differential expressions from those derived from normal immune cells [1-4]. However, little is known about their roles in growth/regulations of cancer cells as well their molecular mechanisms of action [5,6]. These cancerous immunoglobulins differ from those derived from normal immune cells by the presence of a unique carbohydrate-associated epitope which is detected preferentially in the heavy chains of immunoglobulins expressed by cancer cells, but not in normal immune cells. In this report, RP215 was used to study interactions of cancerous immunoglobulins with toll-like receptors in the innate immunity of cancer cells. From gene regulation studies, with OC-3-VGH ovarian and C-33A cervical cancer cell lines, it was demonstrated that the expressions of cancerous toll-like receptors (TLR-2, -3, -4, -6, -7 and -9) are strongly influenced by the incubation of cancer cells with RP215 or antibodies against human IgG. For example, both RP215 and anti-human IgG were found in high correlation to up-regulate TLR-3 expressions by 2.5 and 3.5 fold, respectively, whereas those of TLR-4 and TLR-9 were down-regulated by 50% to 80% of the untreated. Based on these studies, it is reasonable to postulate that cancerous immunoglobulins are functionally related to toll-like receptors in the innate immunity of cancer cells. With RP215 as unique probe for cancerous immunoglobulins, comparative gene regulation studies were performed to investigate interactions or associations between cancerous immunoglobulins or related genes and TLRs in cancer cells. By using semi-quantitative RT-PCR method, results summarized in this review may shed light to our current understanding of cancer immunology which may operate independently of our normal immune system within our body [15,16].

Gene Regulations and Interactions between Cancer Cell-expressed Toll-like Receptors and Immunoglobulins

Toll-like receptors are best characterized family of pattern recognition receptors (PRRs) which recognize foreign microbes derived from bacteria and/or virus, known in general as pathogens-associated molecular patterns (PAMPS) [17-19]. Activation of TLRs with their ligands may evoke inflammatory response and protect the host from spreading massive pathogens after infection. This is commonly known as innate immune response either in normal or cancer cells. So far, at least nine different TLRs and the corresponding ligands have been identified and expressed among different types of cancer in humans [11,20,21].

*Corresponding author: Gregory Lee, UBC Center for Reproductive Health, 9117 Shanghnessy Street, Vancouver, V6P 6R9, Canada, Tel: (778) 322-4651; Fax: (604) 325-4677; E-mail: leecyg@gmail.com

Received December 17, 2013; Accepted February 11, 2014; Published February 17, 2014


Copyright: © 2014 Lee G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Strong influence of RP215 and antibodies against cancerous immunoglobulins on gene regulations of toll-like receptors

Two unrelated cancer cell lines, namely ovarian (OC-3-VGH) and cervical (C-33A) cancer cells were selected for gene regulation studies [4,16]. Upon incubation of RP215 or anti-human IgG with either cancer cells, significant up-regulation (50-100% increase) of NFκB-1 gene was observed. However the effects of these two antibodies on the expressions of immunoglobulins are not as dramatic and consistent [4,16]. No significant increase was observed in gene expressions of IgG in the case of OC-3-VGH cancer cells upon incubations of either RP215 or anti-human IgG. By comparison, up-regulations of IgG were found, with incubation of C-33A cervical cancer cells under the same conditions. The results of this gene regulation analysis are presented and compared in Table 1.

For both OC-3-VGH and C-33A cancer cells, significant and detectable gene expressions of TLRs, including TLR-2, TLR-3, TLR-4, TLR-6, TLR-7 and TLR-9 were observed. However, relative levels of TLR gene expressions vary significantly with the types of cancer cell lines and TLRs [4]. Results of relative expression levels of TLRs in these two types of cancer cells are presented in Figure 1 for comparisons. In the case of OC-3-VGH ovarian cancer cells, TLR-3, TLR-4 and TLR-9 were expressed significantly at higher levels when compared to those by C-33A cervical cancer cells.

On the other hand, C-33A cancer cells were found to express relative high levels of TLR-2, TLR-4 and TLR-9 suitable for further gene regulation and correlation analysis. Upon treatments with RP215 or anti-human IgG, drastic changes in gene expressions of TLRs were observed. Expression levels of selected TLR genes are also presented in Table 1 for comparisons following treatments of two cancer cell lines with either antibody ligand.

In the case of TLR-3 gene, the expression levels were increased upon incubation with RP215 or anti-human IgG by as much as 200% and 150%, respectively, in OC-3VGH ovarian cancer cells. A similar result was observed for significant up-regulation of TLR-3 gene in C-33A cervical cancer cells upon the antibody treatments. When TLR-4 was employed for gene regulation studies, the expression levels were decreased to 10-30% of the untreated negative control in OC-3-VGH cancer cells, whereas those of C-33A cancer cells were down-regulated to 50-70% of the control level.

Similarly, down-regulation of TLR-9 gene was commonly observed for both cell lines upon treatments with either antibody added at 10 μg/ml for 24 hour incubation in either of the two cancer cell culture. In the case of C-33A cancer cells, up-regulation of TLR-2 gene was also observed upon antibody treatments.

High correlations between RP215 and anti-immunoglobulins on gene regulations of toll-like receptors

Both RP215 and anti-human IgG act similarly on gene regulations of selected TLR genes with no exceptions, when two different cancer cell lines were employed for such comparative studies. The results of these gene expression analyses are summarized and presented in Table 1.

From the data presented in Table 1, a correlation analysis was performed to determine the degree of correlation of these two antibody ligands against cancerous immunoglobulins in terms of their respective effect on TLR gene expressions. As presented in Figure 2, a high degree of correlation was obtained when their relative effects on gene regulations are taken into consideration (R²=0.9467).

In a separate study, a monoclonal antibody against TLR-4 was used as the probe to study its effects on gene expression of TLR-4 in cancer cells. Similar to the effects of RP215 or anti-human IgG, anti TLR-4 monoclonal antibody also induces significant down-regulation of TLR-4 gene by as much as 20-30% of the control level in either cancer cell line. Anti-TLR-4 Mab was also found to induce significant apoptosis, similar to that observed for RP215 or anti-human IgG [4,9,22,23]. Unexpectedly, anti-TLR-4 monoclonal antibody has little or no effect on the gene expressions of IgG in either cancer cells following similar gene regulation analysis.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Antibody Ligands</th>
<th>OC-3-VGH</th>
<th>C-33A</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG</td>
<td>RP215</td>
<td>108 ± 2*</td>
<td>160 ± 5</td>
</tr>
<tr>
<td>Anti-human IgG</td>
<td>105 ± 5*</td>
<td>166 ± 4</td>
<td></td>
</tr>
<tr>
<td>NFκB-1</td>
<td>RP215</td>
<td>141 ± 16</td>
<td>182 ± 9</td>
</tr>
<tr>
<td>Anti-human IgG</td>
<td>153 ± 10</td>
<td>176 ± 11</td>
<td></td>
</tr>
<tr>
<td>TLR-3</td>
<td>RP215</td>
<td>326 ± 32</td>
<td>329 ± 12</td>
</tr>
<tr>
<td>Anti-human IgG</td>
<td>243 ± 25</td>
<td>141 ± 18</td>
<td></td>
</tr>
<tr>
<td>TLR-4</td>
<td>RP215</td>
<td>12 ± 9</td>
<td>48 ± 5</td>
</tr>
<tr>
<td>Anti-human IgG</td>
<td>28 ± 18</td>
<td>71 ± 6</td>
<td></td>
</tr>
<tr>
<td>TLR-9</td>
<td>RP215</td>
<td>17 ± 10</td>
<td>39 ± 4</td>
</tr>
<tr>
<td>Anti-human IgG</td>
<td>43 ± 8</td>
<td>60 ± 4</td>
<td></td>
</tr>
</tbody>
</table>

*The gene expression levels of cancer cells without treatments were adjusted to 100%, (based on comparison with the internal control gene of GAPDH)
*Average and standard deviation are presented in each case
*All data presented are statistically significant at P<0.01 except those labeled with * which are not statistical different from the negative control

Table 1: Effects of RP215 and anti-human IgG on Expressions of Selected Genes from OC-3-VGH ovarian and C-33A cervical cancer cells.

Figure 1: Toll-like receptor (TLR) expression levels of OC-3-VGH ovarian and C-33A cervical cancer cell lines. Semi-quantitative RT-PCR was used to reveal relative expression levels of various toll-like receptors including TLR-2 to TLR-9 from cultured OC-3-VGH ovarian ( ) and C-33A cervical ( ) cancer cells, respectively. Lane 1: TLR-2; Lane 2: TLR-3; Lane 3: TLR-4; Lane 4: TLR-6; Lane 5: TLR-7; Lane 6: TLR-9. Expression of GAPDH gene served as the internal control were adjusted to 100%. Percent expression levels of various TLR genes with respect to that of GAPDH are presented for comparisons. Obtained and modified from [4] with permission.
Discussion

Strong unidirectional effects of RP215 or anti-immunoglobulins on gene expressions of toll-like receptors

In this study, efforts have been made to study the effects of RP215 or anti-human IgG on gene regulations of toll-like receptors in the innate immunity of cancer cells. Through gene regulation studies, it was demonstrated that gene expressions of toll-like receptors, especially TLR-3, TLR-4 and TLR-9 in two different cultured cancer cell lines, are strongly influenced by treatments of these two antibody ligands. On the contrary, anti-TLR-4 monoclonal antibody has no effects on gene expression of IgG in cancer cells. This observation seems to suggest that the controls of selected TLR genes by cancerous immunoglobulins are unidirectional. Since toll-like receptors are required for the innate immune system of cancer cells, the expression of cancerous immunoglobulins may in part, explain their requirements for the growth/survival of cancer cells [12,24-28].

NFκB-1 is a key gene regulator

It is interesting to note that NFκB-1 was significantly up-regulated by treatments either with RP215 or antibodies against human IgG in either cancer cells [4,16]. Since NFκB is a transcription factor involved in the activation or expression of as many as 200 genes important for biological functions of various cell types [11,12,20,21,29-32]. Therefore, the associations between cancerous immunoglobulins and toll-like receptors could be highly regulated by NFκB as a common transcription factor [29-32].

Through gene regulation studies, the biosimilarity between RP215 and anti-human IgG was clearly established with respect to their effects on gene regulations of toll-like receptors in cancer cells (Figure 2).

Strong involvements and mutual interactions of cancerous immunoglobulins and toll-like receptors in carcinogenesis of cancer cells

The involvements of TLRs in the carcinogenesis of cancer cells has been extensively investigated [11,12,20,21]. TLRs are known for their abilities to recognize different molecules associated to pathogens, for example lipopolysaccharide (LPS), flagellin, or double strand RNAs [11,12]. TLR-related research has greatly advanced recently and shows that TLRs may also play roles in driving tumorigenesis through stimulation, promoting cancer growth and helping the surveillance of cancer cells against the host immune system [11,12,20,21]. Understanding the mechanism and signaling pathway promises potential therapies against infection, inflammation as well as cancer [11,12,20,21].

We believe that endogenous antigens may be present and hostile to tumor cells in our normal body environment. Cancerous immunoglobulins are required to neutralize these antigens for the protection of cancer cells as additional defense mechanism for the survival and proliferation of cancer cells, similar to those of toll-like receptors in the innate immunity system against foreign pathogens. Therefore, strong interactions of these two systems may have to operate simultaneously with strong interactions.

Clinical significance of cancerous immunoglobulins and toll-like receptors in cancer immunology

Based on results of the present studies, it seems reasonable to suggest that TLRs and cancerous immunoglobulins may play similar or parallel roles in neutralizing undesirable “antigen/pathogen” in the innate immunity of cancer cells [33,34]. Both could play equally important roles for the immune protections in the immune system of cancer cells. Strong interactions between cancerous immunoglobulins and toll-like receptor through a common regulator, or transcription factor such as NFκB cannot be underestimated. This may be one of the most important mechanisms of action for the development of RP215 as an anti-cancer drug during cancer immunotherapy in humans.

Acknowledgements

This research project was supported in parts by NRC-IRAP program (#794354) of Canada. Helpful discussion on this topic with Suefay Liu is acknowledged.

Conflict of Interest

Gregory Lee is co-founder of Vancouver Biotech Ltd. The other two have nothing to declare.

References


